1. Market Research
  2. > Cellulite - Pipeline Review, H2 2013

Cellulite - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 57 pages

Cellulite - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Cellulite - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cellulite, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cellulite. Cellulite - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cellulite.
- A review of the Cellulite products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cellulite pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cellulite.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cellulite pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Cellulite - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cellulite Overview 6
Therapeutics Development 7
Pipeline Products for Cellulite - Overview 7
Pipeline Products for Cellulite - Comparative Analysis 8
Cellulite - Therapeutics under Development by Companies 9
Cellulite - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Cellulite - Products under Development by Companies 13
Cellulite - Companies Involved in Therapeutics Development 14
Auxilium Pharmaceuticals, Inc. 14
Halozyme Therapeutics, Inc. 15
Helix BioMedix, Inc. 16
Kedem Pharmaceuticals Inc. 17
Easton Pharmaceuticals Inc. 18
Cellulite - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Assessment by Therapeutic Class 26
Drug Profiles 28
collagenase clostridium histolyticum - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
HTI-501 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
POS-002 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
HB-2032 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
HB-2031 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
EP-005 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Cellulite - Recent Pipeline Updates 38
Cellulite - Discontinued Products 48
Cellulite - Product Development Milestones 49
Featured News and Press Releases 49
Oct 23, 2013: Auxilium Pharmaceuticals Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticum 49
Oct 23, 2013: BioSpecifics Technologies Announces Initiation of Phase 2a Study of XIAFLEX for Treatment of Cellulite 50
Dec 13, 2012: Auxilium Pharma Announces Encouraging Top-line 30-day Data From Xiaflex Phase Ib Study In Cellulite 51
Jan 31, 2012: Interim Data From Phase I Study Of HTI-501 Support Commencement Of Phase II Portion Of Clinical Trial 52
Jan 26, 2012: Auxilium Announces First Cohort Of Patients Dosed In XIAFLEX Phase Ib Cellulite Study 52
Sep 28, 2011: Halozyme Begins Clinical Trial With HTI-501 In Women With Edematous Fibrosclerotic Panniculopathy 53
Aug 31, 2011: Auxilium And BioSpecifics Announce Plans To Develop Additional Indications Using XIAFLEX 54
May 19, 2008: Halozyme Therapeutics Presents Pre-Clinical Studies on Dermal Remodeling With HTI-501, a Lysosomal Proteinase 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57



List of Tables

Number of Products under Development for Cellulite, H2 2013 7
Number of Products under Development for Cellulite - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Stage Development, H2 2013 11
Comparative Analysis by Unknown Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Cellulite - Pipeline by Auxilium Pharmaceuticals, Inc., H2 2013 14
Cellulite - Pipeline by Halozyme Therapeutics, Inc., H2 2013 15
Cellulite - Pipeline by Helix BioMedix, Inc., H2 2013 16
Cellulite - Pipeline by Kedem Pharmaceuticals Inc., H2 2013 17
Cellulite - Pipeline by Easton Pharmaceuticals Inc., H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 20
Number of Products by Stage and Mechanism of Action, H2 2013 21
Number of Products by Stage and Route of Administration, H2 2013 23
Number of Products by Stage and Molecule Type, H2 2013 25
Number of Products by Stage and Therapeutic Class, H2 2013 27
Cellulite Therapeutics - Recent Pipeline Updates, H2 2013 38
Cellulite - Discontinued Products, H2 2013 48



List of Figures

Number of Products under Development for Cellulite, H2 2013 7
Number of Products under Development for Cellulite - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Top 10 Route of Administration, H2 2013 22
Number of Products by Stage and Top 10 Route of Administration, H2 2013 23
Number of Products by Top 10 Molecule Type, H2 2013 24
Number of Products by Stage and Top 10 Molecule Type, H2 2013 25
Number of Products by Top 10 Therapeutic Class, H2 2013 26
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 27



Companies Mentioned

Auxilium Pharmaceuticals, Inc.
Halozyme Therapeutics, Inc.
Helix BioMedix, Inc.
Kedem Pharmaceuticals Inc.
Easton Pharmaceuticals Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.